The World Health Organization (WHO) has announced its approval of the first malaria treatment specifically designed for infants, known as Coartem Baby, allowing for safe and effective treatment of newborns. This announcement comes at a time when many African countries are facing high rates of malaria infection, with estimates suggesting that around 18% of children under six months may contract the disease.
Malaria accounts for approximately 610,000 deaths annually, with children under five representing the largest proportion of these fatalities. Traditional malaria treatments have relied on medications designed for older children, increasing the risk of dosage errors and side effects.
Details of the Treatment
Coartem Baby is designed to treat children weighing 2 kilograms or more and comes in the form of cherry-flavored tablets that can be dissolved in liquids, including breast milk. Dr. Tedros Adhanom Ghebreyesus, the Director-General of the WHO, stated that this treatment represents a turning point in the fight against malaria, saying, "Malaria has stolen children from their parents, health, wealth, and hope from communities for centuries, but today, the story is changing."
Coartem Baby has received WHO qualification, meaning it meets international standards for quality, safety, and efficacy, making it easier for countries with high malaria rates, particularly in sub-Saharan Africa, to access it.
Background & Context
Historically, it was believed that infants could not contract malaria due to immunity passed from their mothers during pregnancy and breastfeeding. However, recent research has shown that this notion is incorrect, and infants are just as susceptible to malaria as older children. Coartem Baby was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV).
This treatment has already been introduced in Ghana, where an eight-month-old child named "Baby Wonder" was among the first patients to receive the treatment when he was twelve months old. He was hospitalized due to severe fever, and tests confirmed high levels of the malaria parasite in his blood.
Impact & Consequences
This achievement is a significant step towards improving child health in malaria-affected areas, enabling doctors to provide safe and effective treatment for infants who previously had limited therapeutic options. Dr. Martin Fitchett, CEO of MMV, emphasized that this decision represents "a major milestone in public health."
This treatment is expected to contribute to reducing malaria-related mortality rates among children, thereby enhancing community health and restoring hope to families affected by this deadly disease.
Regional Significance
Although malaria is not widespread in Arab countries, this achievement serves as a model for drug development to treat infectious diseases. It may also encourage collaboration between Arab and African nations in public health, contributing to strengthening health capacities and addressing shared health challenges.
In conclusion, Coartem Baby represents an important step towards improving child health globally and reflects ongoing efforts to combat malaria, which remains a significant challenge for many countries.